Quercetin-Enhanced Mitochondrial-Targeted Liposomal Resveratrol Selectively Activates SIRT3 via Compartmentalized NAD+ Boost, Reducing Redox Confounding in Aging Models

Thomas Ito· Mar 26, 2026

Mechanism: Mitochondria-targeted liposomes deliver Quercetin and Resveratrol, preserving resveratrol and selectively boosting mitochondrial NAD+ to activate SIRT3. Readout: Readout: This leads to reduced SOD2-K68 acetylation, decreased mitochondrial ROS, and improved insulin tolerance and oxidative phosphorylation capacity.

Hypothesis

Quercetin co‑encapsulated with resveratrol in mitochondria‑targeted liposomes will increase the mitochondrial NAD⁺/NADH ratio more effectively than free resveratrol, leading to selective SIRT3 activation and deacetylation of SOD2‑K68 without triggering compensatory cytosolic ROS‑SIRT1 signaling.

Rationale

Oral resveratrol suffers rapid glucuronidation/sulfation, limiting systemic exposure 1.
Micronization and liposomal formats raise bioavailability, but liposomes primarily enhance cytosolic/nuclear delivery 2.
Quercetin inhibits sulfotransferases, preserving resveratrol’s aglycone form 3.
Mitochondrial‑targeting ligands (e.g., triphenylphosphonium) direct liposome cargo to the inner membrane, boosting local NAD⁺ pools via stimulation of salvage pathways (NAMPT) 4.
SIRT3 depends on mitochondrial NAD⁺, whereas SIRT1 responds to cytosolic/nuclear NAD⁺ and can be activated indirectly by oxidative stress 5 6.
By concentrating resveratrol and quercetin in mitochondria, we predict a NAD⁺‑driven SIRT3 signal that is separable from stress‑induced SIRT1 activity.

Testable Predictions

NAD⁺ Compartmentalization – Mice receiving mitochondria‑targeted quercetin‑resveratrol liposomes will show a ≥30 % rise in mitochondrial NAD⁺ (measured by Peredox‑mito sensor) versus ≤10 % change in cytosolic NAD⁺ (Peredox‑cyto) after 24 h, while free resveratrol yields <10 % change in both compartments 4 7.
SIRT3‑Specific Deacetylation – Acetyl‑proteomics of liver mitochondria will reveal ≥2‑fold reduction in SOD2‑K68 acetylation and PGC‑1α‑K538 acetylation, with no significant change in cytosolic SIRT1 targets (p53‑K382, NF‑κB p65‑K310) 5 6.
ROS Signaling Decoupling – Mitochondrial ROS (MitoSOX) will decrease, but cytosolic ROS‑sensitive SIRT1 activation markers (phospho‑AMPK, acetyl‑p53) will remain unchanged, indicating absent compensatory stress response 8.
Functional Outcome – In a diet‑induced obesity model, the targeted formulation will improve insulin tolerance (ITT AUC ↓25 %) and increase oxidative phosphorylation capacity (State 3 respiration ↑20 %) compared with free resveratrol or non‑targeted liposomes, effects abolished by SIRT3‑specific shRNA 9 10.

Falsifiability

If mitochondrial NAD⁺ does not rise significantly relative to cytosolic NAD⁺, or if SIRT1 targets show comparable deacetylation to SIRT3 targets, the hypothesis is refuted. Likewise, absence of functional metabolic improvements despite confirmed SIRT3 activation would challenge the predicted mechanistic link.

Novel Mechanistic Insight

Beyond merely boosting bioavailability, quercetin’s sulfation inhibition may preserve resveratrol’s ability to inhibit mitochondrial complex I, causing a mild, transient NADH oxidation that stimulates NAD⁺ salvage via NAMPT. This redox‑neutral shift preferentially enriches the mitochondrial NAD⁺ pool, enabling SIRT3 to act as a “redox buffer” that suppresses ROS without activating stress‑sensitive SIRT1 pathways. Thus, the formulation converts a polyphenol’s intrinsic pro‑oxidant tendency into a compartment‑specific NAD⁺‑centric signal.

Hypothesis

Rationale

Oral resveratrol suffers rapid glucuronidation/sulfation, limiting systemic exposure 1.

Micronization and liposomal formats raise bioavailability, but liposomes primarily enhance cytosolic/nuclear delivery 2.

Quercetin inhibits sulfotransferases, preserving resveratrol’s aglycone form 3.

Mitochondrial‑targeting ligands (e.g., triphenylphosphonium) direct liposome cargo to the inner membrane, boosting local NAD⁺ pools via stimulation of salvage pathways (NAMPT) 4.

SIRT3 depends on mitochondrial NAD⁺, whereas SIRT1 responds to cytosolic/nuclear NAD⁺ and can be activated indirectly by oxidative stress 5 6.

By concentrating resveratrol and quercetin in mitochondria, we predict a NAD⁺‑driven SIRT3 signal that is separable from stress‑induced SIRT1 activity.

Testable Predictions

NAD⁺ Compartmentalization – Mice receiving mitochondria‑targeted quercetin‑resveratrol liposomes will show a ≥30 % rise in mitochondrial NAD⁺ (measured by Peredox‑mito sensor) versus ≤10 % change in cytosolic NAD⁺ (Peredox‑cyto) after 24 h, while free resveratrol yields <10 % change in both compartments 4 7.

SIRT3‑Specific Deacetylation – Acetyl‑proteomics of liver mitochondria will reveal ≥2‑fold reduction in SOD2‑K68 acetylation and PGC‑1α‑K538 acetylation, with no significant change in cytosolic SIRT1 targets (p53‑K382, NF‑κB p65‑K310) 5 6.

ROS Signaling Decoupling – Mitochondrial ROS (MitoSOX) will decrease, but cytosolic ROS‑sensitive SIRT1 activation markers (phospho‑AMPK, acetyl‑p53) will remain unchanged, indicating absent compensatory stress response 8.

Functional Outcome – In a diet‑induced obesity model, the targeted formulation will improve insulin tolerance (ITT AUC ↓25 %) and increase oxidative phosphorylation capacity (State 3 respiration ↑20 %) compared with free resveratrol or non‑targeted liposomes, effects abolished by SIRT3‑specific shRNA 9 10.

Falsifiability

Novel Mechanistic Insight